| Company News |
Swedish Orphan Biovitrum's Kineret® has Received Orphan Drug Designation in the USA Swedish Orphan Biovitrum
(August 26, 2010)
|
Preview - ESC to throw up more than just the hot topics
(August 26, 2010)
|
Daiichi Sankyo Files for Approval to Manufacture and Market AMG 162 (Denosumab) in Japan Daiichi Sankyo
(August 25, 2010)
|
Daily Market Movers (16 Aug 2010)
(August 17, 2010)
|
Therapeutic focus - Vectibix failure leaves few new options for head and neck cancer
(August 16, 2010)
|
Amgen will be disappointed with Vectibix failure
(August 12, 2010)
|
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial Amgen
(August 11, 2010)
|
Dr Reddy's Launches Darbepoetin Alfa in India Under the Brand Name 'Cresp®' Dr. Reddy's Laboratories
(August 09, 2010)
|
Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 Anthera Pharmaceuticals
(July 29, 2010)
|
Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38 Amgen
(July 29, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
| Company Profile |
|
|
| Profile
|
Amgen (AMGN) is a California based biotechnology company, focused on development and commercialisation of human therapeutics for grievous illnesses, based on advances in cellular and molecular biology. |
| Listed or Private Company
|
Listed |
| Company Classification
|
Global Majors; Biotechnology |
| Company Website
|
Website
|
|
Full Company Profile Information
| EventAnalyzer - Last Key Event |
|
| Closing Price DateClosing Price Date
|
EventAnalyzer Note
|
Market Cap (US $m)
|
Change (%)
|
Change (+$m)
|
| 8/16/2010 |
16 Aug: Deutsche Bank initiates coverage with a "hold" rating and price target of $57, citing continued concerns about the impact from the US healthcare reform and EU pricing cuts which could erode the company's sales, and stating that it is unlikely the company will report positive data for osteoporosis treatment, denosumab. |
51,834 |
-1.7% |
-901 |
|
| Top 3 Products (Worldwide Sales 2007/08) |
|
|
| RX Sales Chart |
| Amgen
|
Data
|
Growth
|
|
2007 |
2008 |
2008 |
| Revenues By Segment
|
| Pharmaceuticals
|
| Pharmaceuticals Sales (In-depth)
|
| Rx & OTC Pharmaceuticals
|
| Prescription (Rx) Pharmaceuticals |
14,311 |
14,687 |
|
+3% |
|
|
| Therapy Area Focus in 2008 |
| Amgen
|
|
2008 |
| WW Rx & OTC Sales By Therapy Area
|
| Main Categories
|
| Blood |
5,610 |
| Endocrine |
597 |
| Musculoskeletal |
3,652 |
| Oncology & Immunomodulators |
4,828 |
| Other Rx & OTC Pharma9 |
0 |
|
| EvaluatePharma® Coverage of Marketed and Pipeline Products |
|
|
Product Count
|
| Amgen
10 |
143 |
|
|
|